Skip to main content
Clinical Trials/NCT03110666
NCT03110666
Completed
Phase 4

Treatment for Knee Osteoarthritis With Injections of Autologous Concentrated Bone Marrow Aspirate at the Bone-cartilage Interface Via Percutaneous. Pilot Study

Istituto Ortopedico Rizzoli1 site in 1 country17 target enrollmentNovember 14, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Knee Osteoarthritis
Sponsor
Istituto Ortopedico Rizzoli
Enrollment
17
Locations
1
Primary Endpoint
improvement of the International Knee Documentation Committee (IKDC) subjective score
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This pilot study will evaluate the clinica! and radiological results of a treatment for knee osteoarthritis with injections of autologous concentrated bone marrow aspirate at the bone-cartilage interface via percutaneous.

Detailed Description

This pilot study (N=30) patients will evaluate the clinica! and radiological results of a treatment for knee osteoarthritis with injections of bone marrow concentrate (BMC),obtained from the Bone Marrow Aspirate Concentration System (BioCUE) at the bone-cartilage interface via percutaneous injections. The PerFuse system will also be evaluated to determine if it can be used to deliver the BMC to the osseous sites. Follow-up is 1, 3, 6, 12, and 24 months.

Registry
clinicaltrials.gov
Start Date
November 14, 2016
End Date
May 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • age ranging from 40 to 75
  • Osteoarthritis of the medial or lateral compartment (2-3-4 grade according to the Kellgren-Lawrence score);
  • Failure after at least 6 months of conservative treatment (drug therapy with NSAIDs,hyaluronic acid,platelet-rich plasma and corticosteroids injections);
  • Signature of informed consent.

Exclusion Criteria

  • Patients with trauma in the 6 months prior to the intervention;
  • Patients with malignancies;
  • Patients with rheumatic diseases;
  • Patients with diabetes;
  • Patients suffering from metabolic disorders of the thyroid;
  • Patients being abuse of alcohol, drugs or medications;
  • Body Mass Index\> 35;

Outcomes

Primary Outcomes

improvement of the International Knee Documentation Committee (IKDC) subjective score

Time Frame: Time Frame: 1,3,6, 12, 24 months evaluation

(International Knee Documentation Committee)

Secondary Outcomes

  • evaluation of WORMS score for MRI(Time Frame: 6, 12, 24 months evaluation)
  • improvement of the Knee Injury and osteoarthritis Outcome Score (KOOS)(Time Frame: 1,3,6, 12, 24 months evaluation)

Study Sites (1)

Loading locations...

Similar Trials